First name: Julie
  Last name: Bertrand
  Function: Researcher
  Email: julie.bertrand

Research interest

I am a Biostatistician with an expertise in modelling pharmacokinetic/pharmacodynamic data. My research focuses on the evaluation and development of new inference methods for dynamical processes in order to i) quantify treatment effect or bioequivalence, ii) identify genetic markers of the drug response, iii) jointly infer the survival of events of interest,... In collaboration with clinicians, I have applied my methodological works to the analysis and design of several pharmacological studies.



2009: Ph. D in Biomathematics, University Paris 7

Academic positions

2016-present: Research Fellow, UMR 1137 INSERM University Paris 7

2012-2015: Medical Research Council Research Fellow, University College London Genetics Institute

2010-2012: Research Associate , University College London Genetics Institute

Exhaustive list of publications


Reeves S, Bertrand J, Obee SJ, Hunter S, Howard R, Flanagan RJ
A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status.
British Journal of Clinical Pharmacology 2023

Roughley M, Mena C, Howard R, Reeves S, Bertrand J
Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
British Journal of Clinical Pharmacology 2023

Kerioui M, Bertrand J, Desmée S, Le Tourneau C, Mercier F, Bruno R, Guedj J
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?.
JCO precision oncology 2023, 7, e2200368.


Guhl M, Mercier F, Hofmann C, Sharan S, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentré F, Comets E, Bertrand J
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.
Journal of Pharmacokinetics and Pharmacodynamics 2022, 49, 557-577.

Möllenhoff K, Loingeville F, Bertrand J, Nguyen TT, Sharan S, Zhao L, Fang L, Sun G, Grosser S, Mentré F, Dette H
Efficient model-based bioequivalence testing.
Biostatistics (Oxford, England) 2022, 23, 314-327.

Kerioui M, Bertrand J, Bruno R, Mercier F, Guedj J, Desmée S
Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models.
British Journal of Clinical Pharmacology 2022, 88, 1452-1463.


Couffignal C, Mentré F, Bertrand J
Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.
CPT: pharmacometrics & systems pharmacology 2021, 10, 340-349.

Reeves S, Bertrand J, Uchida H, Yoshida K, Otani Y, Ozer M, Liu KY, Bramon E, Bies R, Pollock BG, Howard R
Towards safer risperidone prescribing in Alzheimer's disease.
The British Journal of Psychiatry: The Journal of Mental Science 2021, 218, 268-275.

Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, Marks M, Guedj J
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.
eLife 2021, 10, e69302.


Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.
CPT: pharmacometrics & systems pharmacology 2020, 9, 509-514.

Kerioui M, Mercier F, Bertrand J, Tardivon C, Bruno R, Guedj J, Desmée S
Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy.
Statistics in Medicine 2020, 39, 4853-4868.

Riglet F, Bertrand J, Barrail-Tran A, Verstuyft C, Michelon H, Benech H, Durrbach A, Furlan V, Barau C
Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
Drugs in R&D 2020, 20, 331-342.

Riglet F, Mentre F, Veyrat-Follet C, Bertrand J
Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
The AAPS journal 2020, 22, 50.

Loingeville F, Bertrand J, Nguyen TT, Sharan S, Feng K, Sun W, Han J, Grosser S, Zhao L, Fang L, Möllenhoff K, Dette H, Mentré F
New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling.
The AAPS journal 2020, 22, 141.


D'Antonio F, Reeves S, Sheng Y, McLachlan E, de Lena C, Howard R, Bertrand J
Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline.
CPT: pharmacometrics & systems pharmacology 2019, 8, 308-315.

Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N, Poupon J, Declèves X, Mentré F, Bellivier F
Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.
European Journal of Clinical Pharmacology 2019, 75, 519-528.


Reeves S, Eggleston K, Cort E, McLachlan E, Brownings S, Nair A, Greaves S, Smith A, Dunn J, Marsden P, Kessler R, Taylor D, Bertrand J, Howard R
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
International Journal of Geriatric Psychiatry 2018, 33, 396-404.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G, A1DSG
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2120-2128.


Reeves S, McLachlan E, Bertrand J, Antonio FD, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Brain: A Journal of Neurology 2017, 140, 1117-1127.

Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J, ASG
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
Antimicrobial Agents and Chemotherapy 2017, 61, e00733-17.

Reeves S, Bertrand J, McLachlan E, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Dunn JT, Marsden P, Kessler R, Uchida H, Taylor D, Howard R
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
The Journal of Clinical Psychiatry 2017, 78, e844-e851.


Tessier A, Bertrand J, Chenel M, Comets E
Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.
CPT: pharmacometrics & systems pharmacology 2016, 5, 123–131.

Reeves S, Bertrand J, D'Antonio F, McLachlan E, Nair A, Brownings S, Greaves S, Smith A, Taylor D, Howard R
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Psychopharmacology 2016, 233, 3371-3381.

Jagani M, Legay H, Ranmal SR, Bertrand J, Ooi K, Tuleu C
Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study.
Pediatrics 2016, 138,


Bertrand J, De Iorio M, Balding DJ
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics.
Pharmacogenetics and Genomics 2015, 25, 231–238.

Tessier A, Bertrand J, Chenel M, Comets E
Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.
The AAPS journal 2015, 17, 597–608.


Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM, C(1CKSG
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
The Journal of Infectious Diseases 2014, 209, 399–408.


Bertrand J, Balding DJ
Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models.
Pharmacogenetics and Genomics 2013, 23, 167–174.


Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW, A1SG
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Pharmacogenetics and Genomics 2012, 22, 868–876.

Bertrand J, Comets E, Chenel M, Mentré F
Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.
Biometrics 2012, 68, 146–155.

Plan EL, Maloney A, Mentré F, Karlsson MO, Bertrand J
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.
The AAPS journal 2012, 14, 420–432.


Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E
Development of a complex parent-metabolite joint population pharmacokinetic model.
The AAPS journal 2011, 13, 390-404.


Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Antimicrobial Agents and Chemotherapy 2010, 54, 4432-4439.


Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F, CA1SG
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
European Journal of Clinical Pharmacology 2009, 65, 667-678.

Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Journal of Pharmacokinetics and Pharmacodynamics 2009, 36, 317-339.


Bertrand J, Comets E, Mentre F
Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Journal of Biopharmaceutical Statistics 2008, 18, 1084-1102.